Literature DB >> 21882942

Conformational adaptation in drug-target interactions and residence time.

Robert A Copeland1.   

Abstract

Although drug-target interactions are commonly illustrated in terms of structurally static binding and dissociation events, such descriptions are inadequate to explain the impact of conformational dynamics on these processes. For high-affinity interactions, both the association and dissociation of drug molecules to and from their targets are often controlled by conformational changes of the target. Conformational adaptation can greatly influence the residence time of a drug on its target (i.e., the lifetime of the binary drug-target complex); long residence time can lead to sustained pharmacology and may also mitigate off-target toxicity. In this perspective, the kinetics of drug-target association and dissociation reactions are explored, with particular emphasis on the impact of conformational adaptation on drug-target residence time.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21882942     DOI: 10.4155/fmc.11.112

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  54 in total

Review 1.  The drug-target residence time model: a 10-year retrospective.

Authors:  Robert A Copeland
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

Review 2.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

3.  Discrimination between conformational selection and induced fit protein-ligand binding using Integrated Global Fit analysis.

Authors:  Franz-Josef Meyer-Almes
Journal:  Eur Biophys J       Date:  2015-11-04       Impact factor: 1.733

4.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

5.  Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors.

Authors:  Johannes Rudolph; Yao Xiao; Arthur Pardi; Natalie G Ahn
Journal:  Biochemistry       Date:  2014-12-04       Impact factor: 3.162

6.  'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Authors:  Georges Vauquelin; David Hall; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

7.  Competitive association binding kinetic assays: a new tool to detect two different binding orientations of a ligand to its target protein under distinct conditions?

Authors:  Hans-Joachim Wittmann; Andrea Strasser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-20       Impact factor: 3.000

Review 8.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

9.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.

Authors:  Wenyu Yu; Emma J Chory; Amy K Wernimont; Wolfram Tempel; Alex Scopton; Alexander Federation; Jason J Marineau; Jun Qi; Dalia Barsyte-Lovejoy; Joanna Yi; Richard Marcellus; Roxana E Iacob; John R Engen; Carly Griffin; Ahmed Aman; Erno Wienholds; Fengling Li; Javier Pineda; Guillermina Estiu; Tatiana Shatseva; Taraneh Hajian; Rima Al-Awar; John E Dick; Masoud Vedadi; Peter J Brown; Cheryl H Arrowsmith; James E Bradner; Matthieu Schapira
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

10.  A Variable Neighbourhood Descent Heuristic for Conformational Search Using a Quantum Annealer.

Authors:  D J J Marchand; M Noori; A Roberts; G Rosenberg; B Woods; U Yildiz; M Coons; D Devore; P Margl
Journal:  Sci Rep       Date:  2019-09-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.